Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Dose Bioequivalence and Adhesion Study of Rotigotina B7 TDS (2 mg/24h) (Rotigotine Transdermal Patch 2 mg/24 Hours) and 'NEUPRO®' (Rotigotine) 2 mg/24 Hours Transdermal Patch in Healthy Adult Human Participants.

NCT07769359 is registered in ClinicalTrials.gov with Amarin Technologies S.A.U. as lead sponsor.

NCT NCT07769359
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07769359 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Dose Bioequivalence and Adhesion Study of Rotigotina B7 TDS (2 mg/24h) (Rotigotine Transdermal Patch 2 mg/24 Hours) and 'NEUPRO®' (Rotigotine) 2 mg/24 Hours Transdermal Patch in Healthy Adult Human Participants.
Lead sponsor
Amarin Technologies S.A.U.
Phase
Phase 1
Overall status
Completed
Start date
December 4, 2025
Completion date
February 26, 2026
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adhesion, adverse effects, bioequivalence